Literature DB >> 17111203

Streptokinase--the drug of choice for thrombolytic therapy.

Adinarayana Kunamneni1, Thaer Taleb Abed Abdelghani, Poluri Ellaiah.   

Abstract

Thrombosis, the blockage of blood vessels with clots, can lead to acute myocardial infarction and ischemic stroke, both leading causes of death. Other than surgical interventions to remove or by pass the blockage, or the generation of collateral vessels to provide a new blood supply, the only treatment available is the administration of thrombolytic agents to dissolve the blood clot. This article describes a comprehensive review of streptokinase (SK). We discuss the biochemistry and molecular biology of SK, describing the mechanism of action, structures, confirmational properties, immunogenecity, chemical modification, and cloning and expression. The production and physico-chemical properties of this SK are also discussed. In this review, considering the properties and characteristics of SK that make it the drug of choice for thrombolytic therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17111203     DOI: 10.1007/s11239-006-9011-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  122 in total

1.  On the kinetics of the reaction between human antiplasmin and plasmin.

Authors:  B Wiman; D Collen
Journal:  Eur J Biochem       Date:  1978-03-15

Review 2.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Assessment of coronary artery patency after thrombolytic therapy: accurate prediction utilizing the combined analysis of three noninvasive markers.

Authors:  S H Hohnloser; M Zabel; W Kasper; T Meinertz; H Just
Journal:  J Am Coll Cardiol       Date:  1991-07       Impact factor: 24.094

4.  The effect of plasmin on the subunit structure of human fibrinogen.

Authors:  S V Pizzo; M L Schwartz; R L Hill; P A McKee
Journal:  J Biol Chem       Date:  1972-02-10       Impact factor: 5.157

5.  Production of streptokinase in continuous culture.

Authors:  B Holmström
Journal:  Appl Microbiol       Date:  1968-01

6.  Multiplicity of rabbit plasminogen. Physical characterization.

Authors:  J M Sodetz; W J Brockway; F J Castellino
Journal:  Biochemistry       Date:  1972-11-21       Impact factor: 3.162

7.  High yield production and purification of recombinant staphylokinase for thrombolytic therapy.

Authors:  B Schlott; M Hartmann; K H Gührs; E Birch-Hirschfeid; H D Pohl; S Vanderschueren; F Van de Werf; A Michoel; D Collen; D Behnke
Journal:  Biotechnology (N Y)       Date:  1994-02

8.  A functional analysis of the antigenicity of streptokinase using monoclonal antibody mapping and recombinant streptokinase fragments.

Authors:  G L Reed; P Kussie; B Parhami-Seren
Journal:  J Immunol       Date:  1993-05-15       Impact factor: 5.422

9.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

10.  Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase--a bacterial plasminogen activator.

Authors:  D Behnke; D Gerlach
Journal:  Mol Gen Genet       Date:  1987-12
View more
  23 in total

Review 1.  Skin microbiota: a source of disease or defence?

Authors:  A L Cogen; V Nizet; R L Gallo
Journal:  Br J Dermatol       Date:  2008-03       Impact factor: 9.302

2.  Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.

Authors:  I Y Sazonova; R A McNamee; A K Houng; S M King; L Hedstrom; G L Reed
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

3.  The evolution of recombinant thrombolytics: Current status and future directions.

Authors:  Yogender Pal Khasa
Journal:  Bioengineered       Date:  2016-10-03       Impact factor: 3.269

4.  Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression.

Authors:  Newton J Hurst; Abdo J Najy; Carolyn V Ustach; Lisa Movilla; Hyeong-Reh Choi Kim
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

5.  Pentoxifylline Increases Antiadhesion Effect of Streptokinase on Postoperative Adhesion Formation: Involvement of Fibrinolytic Pathway.

Authors:  Majid Jafari-Sabet; Azita Shishegar; Ali-Reza Saeedi; Siavash Ghahari
Journal:  Indian J Surg       Date:  2014-01-14       Impact factor: 0.656

6.  An In Vitro Thrombolysis Study Using a Mixture of Fast-Acting and Slower Release Microspheres.

Authors:  Hoai X Nguyen; Edgar A O'Rear
Journal:  Pharm Res       Date:  2016-03-10       Impact factor: 4.200

7.  Pitfalls in screening streptococci for retrieving superior streptokinase (SK) genes: no activity correlation for streptococcal culture supernatant and recombinant SK.

Authors:  Malihe Keramati; Farzin Roohvand; Mohammad Mehdi Aslani; Fatemeh Motevalli; Shohreh Khatami; Arash Memarnejadian
Journal:  J Ind Microbiol Biotechnol       Date:  2012-10-25       Impact factor: 3.346

8.  A bioconjugated polyglycerol dendrimer with glucose sensing properties.

Authors:  Edson Giuliani Ramos Fernandes; Alvaro Antonio Alencar De Queiroz
Journal:  J Mater Sci Mater Med       Date:  2008-10-14       Impact factor: 3.896

Review 9.  Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.

Authors:  Anna N Ilinskaya; Marina A Dobrovolskaia
Journal:  Toxicol Appl Pharmacol       Date:  2016-01-07       Impact factor: 4.219

Review 10.  Jugular thrombophlebitis in horses: a review of fibrinolysis, thrombus formation, and clinical management.

Authors:  Deborah Penteado Martins Dias; José Corrêa de Lacerda Neto
Journal:  Can Vet J       Date:  2013-01       Impact factor: 1.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.